Summary & Overview
HCPCS Level II Q2028: Sculptra Injection, 0.5 mg
HCPCS Level II code Q2028 denotes a 0.5 mg injection of Sculptra, a poly-L-lactic acid soft-tissue filler used primarily for cosmetic facial volume restoration. Nationally, accurate coding for Sculptra injections matters for billing clarity, payer adjudication, and collection of utilization data for aesthetic injectable products.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical intent and common sites of service for Sculptra injections, alongside typical payer coverage considerations and commonly reported modifiers. The publication outlines benchmarks and reimbursement context where available, highlights policy themes that affect coverage of injectable aesthetic products, and provides coding precision to support clean claims submission.
This analysis is intended for a national audience of clinicians, billing professionals, and administrators seeking clear guidance on the purpose of Q2028, payer landscape, and the operational considerations that commonly arise when billing for Sculptra injections. Data not available in the input is identified explicitly elsewhere in the publication.
Billing Code Overview
HCPCS Level II code Q2028 represents an injection of Sculptra, dosed at 0.5 mg per unit. This code is used to report administration of the poly-L-lactic acid product indicated for aesthetic soft tissue augmentation.
Service type: Injectable soft-tissue filler / cosmetic dermatologic procedure
Typical site of service: Outpatient clinic, dermatology or plastic surgery office, or ambulatory surgical center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult seeking cosmetic soft tissue augmentation to restore facial volume and correct shallow to moderate facial folds. The patient presents to an outpatient dermatology or plastic surgery clinic for evaluation of age-related volume loss of the midface, cheeks, or nasolabial folds. After medical history and informed consent, the provider prepares sterile Sculptra (poly-L-lactic acid) for injection. Treatment is performed in the office-based procedure room or an ambulatory surgery center under local anesthesia or topical numbing; multiple injection sessions spaced several weeks apart are commonly planned. The billed unit Q2028 (Injection, sculptra, 0.5 mg) is recorded per 0.5 mg vial amount used. Typical workflow steps: pre-procedure assessment and photography, marking treatment areas, aseptic preparation, local anesthesia as needed, staged intradermal/subcutaneous injections of Sculptra with appropriate dilution and reconstitution, post-injection instructions, and scheduling follow-up treatments. The procedure is typically elective, medically indicated for cosmetic facial rejuvenation, and performed by board-certified dermatologists, plastic surgeons, or qualified cosmetic practitioners.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |